Keyphrases
Interleukin-17 (IL-17)
100%
Immune Response
100%
Vaccination
100%
Allogeneic
100%
CD4+
100%
Dendritic Cells
100%
Primary Brain Tumor
100%
Dendritic Cell Vaccine
100%
Brain Cancer Cells
100%
Dose Escalation
33%
Maximum Tolerated Dose
33%
Dose-limiting Toxicity
33%
Tumor Response
33%
Cell-to-cell
33%
Lymphocytes
33%
Cell Population
33%
Novel Vaccines
33%
Myeloid-derived Suppressor Cells
33%
Stable Disease
33%
First-in-human Study
33%
Subcutaneous Injection
33%
Flow Cytometric
33%
Overall Survival
33%
Flow Cytometry
33%
Autologous Dendritic Cells
33%
Partial Response
33%
Time to Progression
33%
Best Response
33%
Tumor Cell Lines
33%
Cell Dose
33%
Allogeneic Vaccine
33%
McDonald Criteria
33%
Clinical Outcomes
33%
Large-scale Investigation
33%
Immune Profiling
33%
Medicine and Dentistry
Brain Cancer
100%
Tumor Cell
100%
Intracranial Tumor
100%
Dendritic Cell
100%
Immune Response
60%
Dendritic Cell Vaccine
40%
Neoplasm
20%
Myeloid-Derived Suppressor Cell
20%
Subcutaneous Injection
20%
Cell Population
20%
Flow Cytometry
20%
Human Study
20%
Overall Survival
20%
Brain Tumor Cell Line
20%
McDonald Criteria
20%
Lymphocyte
20%
Diseases
20%
Immunology and Microbiology
Dendritic Cell
100%
CD4
100%
Tumor Cell
100%
Immune Response
60%
Dendritic Cell Vaccine
40%
Myeloid-Derived Suppressor Cell
20%
Overall Survival
20%
Cell Population
20%
Maximum Permissible Dose
20%
McDonald Criteria
20%
Brain Tumor Cell Line
20%
Lymphocyte
20%
Pharmacology, Toxicology and Pharmaceutical Science
Brain Cancer
100%
Intracranial Tumor
100%
Dendritic Cell Vaccine
66%
Human Study
33%
Flow Cytometry
33%
Overall Survival
33%
Neoplasm
33%
Subcutaneous Injection
33%
Diseases
33%